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https://doi.org/10.101T(4;11) MLL-AF4 acute leukemia is one of the most aggressive malignancies in infant
and pediatric populations. Epidemiological and functional studies have highlighted the
influence of an overstimulation of the immune system on leukemia development. This
study aimed at assessing if the cell-of-origin of t(4;11) MLL-AF4 acute leukemia is sen-
sitive to a viral or bacterial mimic and if maternal immune activation can lead to a
full-blown leukemia. To answer this, we used the Mll-AF4 pre-leukemia mouse model
that initiates the expression of Mll-AF4 in the first definitive hematopoietic cells formed
during embryonic development. We observed an increase in proliferation upon hemato-
poietic differentiation of fetal liver Mll-AF4+ Lineage−Sca1+ckit+ (LSK) cells exposed
to the immune stimulants, poly(I:C) or LPS/lipopolysaccharide. This was accompanied
by increased expression of a subset of MLL-AF4 signature genes and members of the
Toll-like receptor signaling pathways in fetal liver Mll-AF4+ LSK exposed to poly(I:C),
suggesting that the cell-of-origin responds to inflammatory stimuli. Maternal immune
activation using a single dose of poly(I:C) did not lead to the development of leukemia
in Mll-AF4+ and control offspring. Instead, aging MLL-AF4+ mice showed an
increased proportion of T-lymphoid cells in the spleen, lost their B-lymphoid bias, and
had decreased frequencies of hematopoietic stem and multipotent progenitor cells.
Overall, this study suggests that the fetal liver Mll-AF4+ LSK cells are sensitive to
direct exposure to inflammatory stimuli, especially poly(I:C); however, maternal
immune activation induced by a single exposure to poly(I:C) is not sufficient to initiate
MLL-AF4 leukemogenesis. © 2019 ISEH – Society for Hematology and Stem Cells.
Published by Elsevier Inc. This is an open access article under the CC BY license.
(http://creativecommons.org/licenses/by/4.0/)T(4;11) MLL-AF4 acute lymphoblastic leukemia is an
aggressive subtype of infant and pediatric leukemia that
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6/j.exphem.2019.07.004reported a 100% penetrance [1]. We are starting to gain
more insight into how the disease develops through the
use of pre-leukemia and leukemia mouse models [2−8].
Using a pre-leukemia mouse model, in which expression
of Mll-AF4 initiates in all definitive hematopoietic cells
formed during embryonic development (Mll-AF4 invertor
mouse crossed with VEC-Cre), we previously identified
the fetal liver as the starting point of MLL-AF4-driven leu-
kemogenesis [4,7]. At this stage, Mll-AF4 expression
increases the engraftment and self-renewal potential of
hematopoietic stem and immature progenitor cells (Lineage
−Sca1+ckit+ [LSK] cells), but also induces a high B-lym-
phoid clonogenic bias.by Elsevier Inc. This is an open access article under the CC BY license.
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kemia is largely unknown. One theory in the pediatric
leukemia field is that leukemogenesis requires addi-
tional stress signals, such as an overstimulation of the
inflammatory response [9−11]. Although there is strong
evidence supporting the role of infections as triggers of
leukemia in older children, it is currently unknown
whether an abnormal stimulation of the immune system
during gestation also triggers leukemia in infants. We
therefore decided to investigate if fetal liver Mll-AF4+
LSK cells from the pre-leukemia mouse model were
sensitive to viral or bacterial mimics through use of the
double-stranded RNA viral analog polyinosinic:polycy-
tidylic acid (poly(I:C)) or the bacterial endotoxin lipo-
polysaccharide (LPS). These molecules bind the Toll-
like receptors Tlr3 and Tlr4, respectively, which are
crucial to adaptive immunity (reviewed in [12]). They
can also increase the proliferation of adult hematopoi-
etic stem and progenitor cells [13−15]. We assessed
how both mimics influence myeloid and B-lymphoid
clonogenic potential, differentiation, and proliferation,
but also the expression of MLL-AF4 signature genes.
Although in vitro stimulation of fetal liver Mll-AF4+
LSK cells with poly(I:C) or LPS had no effect on mye-
loid or B-lymphoid hematopoietic clonogenic potential,
poly(I:C) was able to increase proliferation in myeloid
and B-lymphoid conditions, whereas LPS increased
proliferation in B-lymphoid conditions only. In addi-
tion, exposure to poly(I:C), but not LPS, upregulated
the expression of MLL-AF4 signature genes (Mll-AF4,
Mll, Af4, Cdk6, Hmga2, Hoxa9, Il7r, Lmo2, and Mcl1)
and members of the Toll-like signaling pathways (Tlr9,
Mda5, and Rig1) in fetal liver Mll-AF4+ LSK cells.
We also induced a maternal immune activation (MIA)
with poly(I:C) to assess its effect on MLL-AF4-driven
leukemogenesis in the offspring. We found that a sin-
gle intraperitoneal injection of poly(I:C) at E14−E15
was not sufficient to trigger MLL-AF4 leukemogenesis.
Instead, Mll-AF4+VEC-Cre+ aging mice showed an
increase of CD3+ T-lymphoid cells in the spleen, main-
tained their progenitor B-cell pool, and had a lower
proportion of hematopoietic stem cells (HSCs) and
multipotent progenitors (MPPs). This study suggests
that fetal liver MLL-AF4+ LSK cells are sensitive to
viral and bacterial mimics that can activate the Toll-
like receptor signaling pathways, but a single maternal
immune activation is not enough to initiate and/or
maintain MLL-AF4-driven leukemogenesis.Methods
Mice
All animal work was carried out under the regulation of the
UK Home Office. The Mll-AF4 line was obtained from
Professor Terry Rabbitts [2], and the VEC-Cre line fromProfessor Nancy Speck [16]. Males and females were mated
for embryo generation, with the day of the plug counted as
day 0 of embryonic development. For in vivo stimulation,
pregnant females received a single intraperitoneal injection
of 4 or 10 mg/kg poly(I:C) (Sigma Catalog No. P0913) at
E14−E15 of embryonic development.
Sorting of E14 fetal liver LSK cells
Fetal livers were dissected and dissociated in Flow Cytome-
try Staining Buffer (ThermoFisher Catalog No. 00-4222-26)
using a 21G£ 15-mm needle attached to a syringe (BD
Microlance Catalog Nos. 10472204-X and 3000185). Dissoci-
ated fetal livers were stained using the following antibody
mix in Flow Cytometry Staining Buffer (ThermoFisher Cata-
log No. 00-4222-26): APC anti-mouse CD3e antibody (clone
I45-2C11, Biolegend Catalog No. 100312), APC anti-mouse
TER-119 antibody (clone TER119, Biolegend Catalog No.
116212), APC anti-mouse F4/80 antibody (clone BM8, Biole-
gend Catalog No. 123116), APC anti-mouse Nk1.1 antibody
(clone PK136, Biolegend Catalog No. 108709), APC anti-
mouse Ly-6G/Ly-6C (Gr-1) antibody (clone RB6-8C5, Biole-
gend Catalog No. 108412), PE/Cy7 anti-mouse/human
CD45R/B220 antibody (clone RA3-6B2, Biolegend Catalog
No. 103222), PE/Cy7 anti-mouse CD19 antibody (clone 6D5,
Biolegend Catalog No. 115520), CD117 (ckit) monoclonal
antibody APC-eFluor 780, eBioscience (clone 2B8, Thermo-
Fisher Catalog No. 47-1171-80), Alexa Fluor 700 anti-mouse
CD45 antibody (clone 30-F11, Biolegend Catalog No.
103128), Pacific Blue anti-mouse Ly-6A/E (Sca1) antibody
(Clone E13-161.7, Biolegend Catalog No. 122519). Cells
were incubated for 20 min on ice, washed twice with Flow
Cytometry Staining Buffer, and resuspended in diluted
SYTOX Green Nucleic Acid Stain (ThermoFisher Catalog
No. S7020) to exclude dead cells. Sorting was done on a BD
FACSAria II (BD Biosciences).
In vitro treatment of E14 fetal liver LSK cells
Mll-AF4+ LSK cells were plated for 48 hours in Stem-Pro34
SFM (1£) medium (ThermoFisher Scientific Catalog No.
10639011) supplemented with the following cytokines: stem
cell factor (SCF, 100 ng/mL), FLT3 ligand (50 ng/mL), and
thrombopoietin (TPO, 100 ng/mL) (Peprotech Catalog Nos.
250-03, 250-31L, and 315-14). Poly(I:C) or LPS was added
at 100 ng/mL (Sigma, Catalog Nos. P0913 and L3023).
Mock condition is sterile phosphate-buffered saline (PBS).
Apoptosis assay
Detection of apoptotic cells was achieved through double-
staining using phycoerythrin (PE)-AnnexinV (Biolegend Cat-
alog No. 640907) and SYTOX Blue Dead Cell Stain (Ther-
moFisher Catalog No. S34857). Cells were stained in the
Annexin V Binding Buffer according to the manufacturer’s
instructions (BD Biosciences Catalog No. 556454). Data
were acquired on a BD LSRFortessa (BD Biosciences).
CFU-C assays
Myeloid and lymphoid colony-forming unit cell (CFU-C)
assays were carried out in MethoCult GF M3434 and Metho-
Cult M3630, respectively (STEMCELL Technologies Catalog
C. Malouf and K. Ottersbach / Experimental Hematology 2019;76:49−59 51Nos. 03434 and 03630). For lymphoid CFU-C assays, the fol-
lowing additional cytokines were added: SCF (25 ng/mL) and
FLT3 ligand (20 ng/mL) (Peprotech Catalog Nos. 250-03 and
250-31L). Poly(I:C) or LPS was added at 100 ng/mL. Mock
condition is sterile PBS.
Flow cytometry analysis of peripheral blood and tissues
For flow cytometry of peripheral blood and tissues, red blood
cell lysis was carried out with BD Pharm Lyse lysing solu-
tion according to the manufacturer’s instructions (BD Bio-
sciences Catalog No. 555899). Cells were stained in Flow
Cytometry Staining Buffer using the following mixture of
antibodies for differentiated cells: APC anti-mouse CD45
antibody (clone 30-F11, Biolegend Catalog No. 103111),
eFluor450-CD11b monoclonal antibody eBioscience (clone
M1/70, ThermoFisher Catalog No. 48-0112-80), Alexa Fluor
700 anti-mouse Ly-6G/Ly-6C (Gr1) antibody (clone RB6-
8C5, Biolegend Catalog No. 108422), PE/Cy7 anti-mouse/
human CD45R/B220 antibody (clone RA3-6B2, Biolegend
Catalog No. 103222), Brilliant Violet 605 anti-mouse CD19
antibody (clone 6D5, Biolegend Catalog No. 115539), anti-
gen presenting cell (APC)-eF780 IgM mouse monoclonal
antibody (clone II/41, ThermoFisher Catalog No. 47-5790-
82), PE-CD3 anti-mouse antibody (clone 145-2C11, Biole-
gend Catalog No. 100308). For progenitor and precursor B
cells, we used the following antibodies: fluorescein isothiocy-
anate (FITC) anti-mouse CD43 activation-associated glyco-
form antibody (clone 1B11, Biolegend Catalog No. 121206);
Alexa Fluor 700 anti-mouse/human CD45R/B220 (clone
RA3-6B2, Biolegend Catalog No. 103231); Brilliant Violet
421 anti-mouse CD45 (c-antibody, clone 30F11, Biolegend
Catalog No. 103133); PE/Cy7 anti-mouse CD24 antibody
(clone M1/69, Biolegend Catalog No. 101821); APC IgM
mouse monoclonal antibody (clone II/41, ThermoFisher Cata-
log No. 17-5790-82); Brilliant Violet 605 anti-mouse CD19
antibody (clone 6D5, Biolegend Catalog No. 115539);
CD117 (ckit) monoclonal antibody APC-eFluor 780, eBio-
science (clone 2B8, ThermoFisher Catalog No. 47-1171-80);
and PE anti-mouse CD127 (IL7Ra) antibody (clone A7R34,
Biolegend Catalog No. 135010). For hematopoietic stem and
progenitor cells, we used the following antibodies: APC anti-
mouse CD3e antibody (clone I45-2C11, Biolegend Catalog
No. 100312); APC anti-mouse TER-119 antibody (clone
TER119, Biolegend Catalog No. 116212); APC anti-mouse
F4/80 antibody (clone BM8, Biolegend Catalog No. 123116);
APC anti-mouse Nk1.1 antibody (clone PK136, Biolegend
Catalog No. 108709); APC anti-mouse Ly-6G/Ly-6C (Gr1)
antibody (clone RB6-8C5, Biolegend Catalog No. 108412);
APC anti-mouse/human CD45R/B220 antibody (clone RA3-
6B2, Biolegend Catalog No. 103212); APC anti-mouse CD19
antibody (clone 6D5, Biolegend Catalog No. 115512);
CD117 (ckit) monoclonal antibody APC-eFluor 780, eBio-
science (clone 2B8, ThermoFisher Catalog No. 47-1171-80);
Alexa Fluor 700 anti-mouse CD48 antibody (clone HM48-1,
Biolegend Catalog No. 103425), PE/Cy7 anti-mouse CD150
antibody (clone TC15-12F12.2, Biolegend Catalog No.
115914); Pacific Blue anti-mouse Ly-6A/E (Sca1) antibody
(clone E13-161.7, Biolegend Catalog No. 122519); FITC anti-
mouse CD34 antibody (clone RAM34, BD Biosciences Catalog
No. 560238); PE anti-mouse CD127 (IL7Ra) antibody (cloneA7R34, Biolegend Catalog No. 135010); and biotin anti-mouse
CD135 (FLT3) antibody (clone A2F10, ThermoFisher Catalog
No. 13-1351-85) conjugated to Qdot655 streptavidin conjugate
(ThermoFisher, Cat#Q10121MP). Cells were incubated on ice for
20 min, washed twice with Flow Cytometry Staining Buffer, and
resuspended in diluted SYTOX AADvanced (ThermoFisher Cata-
log No. S10274) to exclude dead cells. Data were acquired on a
BD LSRFortessa.
Quantitative RT-qPCR
RNA was extracted using the RNeasy Micro Kit (Qiagen
Catalog No. 74004). For reverse transcription of mRNA, we
used the iScript Advanced cDNA synthesis kit for real-time
reverse transcription quantitative polymerase chain reaction
(RT-qPCR; Bio-Rad Laboratories Catalog No. 1725037)
according to the manufacturer’s instructions. Primers were
designed using Primer3 and tested. Primer sequences can be
found in Supplementary Table E1 (online only, available at
www.exphem.org). We used the Brilliant III Ultra-Fast
SYBR Green qPCR Master Mix according to the man-
ufacturer’s instructions (Agilent Catalog No. 600883). Data
were acquired on a QuantStudio 7 Flex Real-Time PCR Sys-
tem (ThermoFisher).
Data analysis
Flow cytometry data were analyzed using FlowJo. Graphs were
generated using GraphPad Prism 6 (GraphPad Software). Statisti-
cal differences were assessed using GraphPad with a nonparamet-
ric Mann−Whitney U test, a nonparametric Wilcoxon paired test
(RT-qPCR only), or a Gehan−Breslow−Wilcoxon test (survival
curve) with a bilateral p value, as indicated in the figure legends
(*p < 0.05, **p < 0.01, ***p < 0.001).
Results
Poly(I:C) and LPS increase the proliferation of
hematopoietic cells derived from fetal liver Mll-AF4+
hematopoietic stem and progenitor cells in vitro
First, we wanted to assess the direct effect of poly(I:C)
or LPS on fetal liver (FL) Mll-AF4+ hematopoietic
stem and progenitor cells (LSK cells). FL Mll-AF4+
LSK cells were sorted from the MLL-AF4+ pre-leuke-
mia mouse model according to our previous studies
and plated in medium with PBS (mock condition), poly
(I:C), or LPS (Figure 1A) [4,7]. After 48 hours in cul-
ture, Mll-AF4+ LSK cells were counted and plated in
methylcellulose to assess the effect of poly(I:C) or LPS
on myeloid and B-lymphoid clonogenic potential, pro-
liferation, and differentiation, with continued exposure
to mimics. We also collected FL Mll-AF4+ LSK
exposed to poly(I:C) and LPS to measure the expres-
sion of members of the Toll-like receptor signaling
pathway and MLL-AF4 signature genes.
FL Mll-AF4+ LSK expressed both Tlr3 and Tlr4
receptors, which are recognized by poly(I:C) and LPS,
respectively (Figure 1B, C). Tlr3 expression was signif-
icantly upregulated following LPS treatment, whereas
Figure 1. Poly(I:C) and LPS increase the proliferation of hematopoietic cells derived from fetal liver Mll-AF4+ hematopoietic stem and progen-
itor cells in vitro. (A) Experimental layout for the colony-forming assays (CFU-C) and quantitative PCR. Expression of (B) Tlr3 and (C) Tlr4 in
FL Mll-AF4+ LSK cells after a 48-hour in vitro stimulation to mock/PBS, poly(I:C), or LPS. (D) Cell expansion of FL Mll-AF4+ LSK cells
after a 48-hour in vitro stimulation to mock, poly(I:C), or LPS. (E) Apoptosis of FL Mll-AF4+ LSK after a 48-hour in vitro stimulation to
mock, poly(I:C), or LPS. Apoptotic cells are AnnexinV+SytoxBlue−. (F) Myeloid or (G) B-lymphoid colony-forming assay of FL Mll-AF4+
LSK cells plated with mock/PBS, poly(I:C), or LPS. (H) Proliferation of FL Mll-AF4+ LSK cells in myeloid and B-lymphoid colony-forming
assays. Differentiation of (I) myeloid and (J) B-lymphoid cells in colony-forming assays. Expression of (K) Tlr7, (L) Tlr9, (M) Mda5, (N)
Rig1, and (O) Cgas. Statistical differences were assessed using a nonparametric Mann−Whitney U test or Wilcoxon test (RT-qPCR) with a
bilateral p value (*p < 0.05, **p < 0.01, ***p < 0.001; n = 3 or 4).
52 C. Malouf and K. Ottersbach / Experimental Hematology 2019;76:49−59Tlr4 expression remained unchanged. There was no sig-
nificant expansion of FL Mll-AF4+ LSK cells in vitro
in the presence of poly(I:C) or LPS over the 48 hours
(Figure 1D). The level of apoptosis (AnnexinV
+SytoxBlue cells) was also similar for all three con-
ditions (Figure 1E). There was also no significant dif-
ference in the myeloid or B-lymphoid clonogenic
output (Figure 1F, G). Interestingly, counting total cell
numbers on CFU-C plates revealed an expansion of
myeloid cells upon poly(I:C) treatment and an evenmore pronounced expansion of B-lymphoid cells upon
either poly(I:C) or LPS treatment (Figure 1H). This
was a general effect as the relative proportions of cell
types were maintained (Figure 1I,J).
We assessed the expression of members of the Toll-like
receptor signaling pathway in FL Mll-AF4+ LSK cells
stimulated with poly(I:C) or LPS. Poly(I:C) did not affect
the expression of Tlr7, but increased the expression of
Tlr9 (Figure 1K, L). Both Toll-like receptors are found on
endosomes and are activated by the presence of viral
C. Malouf and K. Ottersbach / Experimental Hematology 2019;76:49−59 53RNA. Mda5 and Rig1, two viral sensors, were also upre-
gulated in FL Mll-AF4+ LSK cells upon poly(I:C) treat-
ment (Figure 1M, N). Cgas, a double-stranded DNA
sensor, maintained a similar expression upon poly(I:C) or
LPS treatment (Figure 1O). Sensors of cytosolic RNA and
DNA pathways such as Tlr9, Mda5, and Rig1 can induce a
pro-inflammatory phenotype through the activation of
interferon (IFN)-stimulated genes (reviewed in [17]).
These results indicate that hematopoietic cells derived
from FL Mll-AF4+ LSK cells increase their proliferation
in the presence of viral or bacterial stimuli, and also upre-
gulate the expression of components of the Toll-likeFigure 2. Poly(I:C) affects the MLL-AF4 signature gene expression progra
vitro. Expression of (A) Mll-AF4, (B) Mll, (C) Af4, (D) Cdk6, (E) Hmga2
(L) E2a, (M) Ikaros, (N) Pax5, (O) Il7r, and (P) Flt3 in FL Mll-AF4+ LS
LPS. Expression of (Q) Tlr3, (R) Tlr4, (S) Mll, (T) Af4, (U) Hmga2, (V) H
after a 48-hour in vitro stimulation with mock/PBS, poly(I:C), or LPS. S
test with a bilateral p value (*p < 0.05, **p < 0.01, p < 0.001; n = 3 or 4).receptor signaling pathway; however, clonogenic potential
was unaffected.
Poly(I:C) affects the MLL-AF4 signature gene
expression program in fetal liver Mll-AF4+
hematopoietic stem and progenitor cells
We verified the expression of a subset of genes that are
involved in MLL-AF4-driven leukemogenesis in FL
Mll-AF4+ LSK cells stimulated with poly(I:C) or LPS.
The expression of Mll-AF4, Mll, Af4, Cdk6, Hmga2,
Hoxa9, Lmo2, and Mcl1 was upregulated in vitro by
poly(I:C), but not LPS (Figure 2A−H). By contrast,m in fetal liver Mll-AF4+ hematopoietic stem and progenitor cells in
, (F) Hoxa9, (G) Lmo2, (H) Mcl1, (I) Meis1, (J) Bcl2, (K) Twist1,
K after a 48-hour in vitro stimulation with mock/PBS, poly(I:C), or
oxa9, and (W) Cdk6 in FL control (Mll-AF4−VEC-Cre+) LSK cells
tatistical differences were assessed using a nonparametric Wilcoxon
54 C. Malouf and K. Ottersbach / Experimental Hematology 2019;76:49−59Meis1 and Bcl2 were slightly downregulated upon LPS
exposure, whereas poly(I:C) did not affect them
(Figure 2I,J). The expression of Twist1, E2a, Ikaros,
and Pax5 remained similar for all three conditions
(Figure 2K−N). Il7r expression significantly increased
upon poly(I:C) exposure, which was accompanied by a
downregulation of Flt3 (Figure 2O,P). Overall, these
results suggest that an inflammatory stimulus that
mimics a viral component can directly affect the
expression of MLL-AF4 signature genes in FL Mll-
AF4+ LSK cells. However, as discussed earlier, these
changes are not sufficient to affect the hematopoietic
clonogenic or differentiation potential of FL Mll-AF4+
LSK. To determine whether this is a more general
effect, independent of Mll-AF4 expression, we checked
the expression of Tlr3, Tlr4, Mll, Af4, Cdk6, Hmga2,
and Hoxa9 in control FL LSK (Mll-AF4−VEC-Cre+)
cells. Interestingly, the pattern was quite different, as
an exposure to poly(I:C) led to a downregulation of
Tlr3, Tlr4, Mll, Af4, Hmga2, and Hoxa9 compared with
mock or LPS-treated cells (Figure 2Q−V). Cdk6
expression was stable in control FL LSK cells regard-
less of the condition (Figure 2W). Therefore, the Mll-
AF4 expression signature can be modulated by a direct
exposure to poly(I:C), but this requires the presence of
the oncogenic driver.
A poly(I:C)-induced maternal immune activation is not
sufficient to drive Mll-AF4 leukemogenesis
As we found poly(I:C) to be a positive modulator of
proliferation of myeloid and B-lymphoid hematopoietic
cells derived from FL Mll-AF4+ LSK cells and to
affect members of the MLL-AF4 signature gene
expression, we decided to assess its effect on hemato-
poietic development in vivo. Although there is no
strong evidence that poly(I:C) can penetrate the placen-
tal barrier to reach the fetal liver, the intraperitoneal
injection of poly(I:C) in a pregnant dam can activate
the innate immune response, leading to increased levels
of cytokines in the maternal compartment (reviewed in
[18]). This compromises the integrity of the maternal−fetal
barrier, leading to dissemination of maternal cytokines to
the embryo. Given the very short latency of infant t(4;11)
MLL-AF4 acute leukemia, we wanted to assess if the
maternal immune response could promote MLL-AF4-driven
leukemogenesis. Pregnant dams received a single intraperi-
toneal injection of poly(I:C) at E14−E15 of embryonic
development. This is the same developmental time point
used in the in vitro analysis (Figures 1 and 2). Pups were
born without complications and were monitored for a
period of 18 months to assess disease development. Only 3
of 12 Mll-AF4+VEC-Cre+ mice developed a disease
that was linked to a sudden death (NB1: 10 day-old) or
splenomegaly (1463: 564 days old, and 1681: 516 days
old) (Figure 3A). Overall, the latency in the Mll-AF4+VEC−Cre+ cohort was significantly shorter compared with
that in the Mll-AF4VEC-Cre+/ control. Sick and end-
of-study Mll-AF4+VEC-Cre+ mice had a lower weight
compared with control mice (Figure 3B), but no
overall significant difference in spleen or liver weight
(Figure 3C,D). Mice 1463 and 1681 presented with spleno-
megaly, which was absent in the control mice, and a red
bone marrow (Figure 3E). We analyzed the hematopoietic
compartment in the bone marrow, spleen, and peripheral
blood for mice 1463 and 1681 and compared the results
with those of age-matched control mice. Mouse 1463
showed a decrease of CD11b+ myeloid cells in the bone
marrow and spleen and a decrease of B220+ B-lymphoid
cells in the spleen and peripheral blood (Figure 3F−H).
Similarly, mouse 1681 showed a decrease in CD11b+ mye-
loid cells in the spleen and a decrease in CD3+ T-lymphoid
and B220+ B-lymphoid cells in all three compartments
(Figure 3F−H). In the peripheral blood, both sick mice
showed a drop in white blood cell, red blood cell, and
platelet counts compared with age-matched control mice
(Figure 3I−K). Together, this evidence suggests that mice
1463 and 1681 developed not a leukemia, but a hematolog-
ical malignancy that is similar to a myelodysplastic syn-
drome (Figure 3P).
NB1 mouse had a slightly enlarged spleen (35.7 mg)
compared with age-matched control mice (28.75 mg)
and a pale liver (Figure 3L). In the bone marrow, there
was a decrease in CD11b+ myeloid cells while the
numbers of CD3+ T-lymphoid cells and B220+ CD19+
B-lymphoid cells were normal (Figure 3M). Most nota-
ble was the expansion of B220+CD19− cells, which
are almost absent in the control mice (Figure 3M).
These B220+CD19− cells were also detected in the
spleen alongside an increase in CD11b+ myeloid cells
(Figure 3N). The B220+CD19− cells were also IgM−
(Figure 3O). This cell population has been observed in
Pax5 haploinsufficient mice that developed a pre-B
acute lymphoblastic leukemia when their immune sys-
tem was overstimulated [10]. However, we could not
assess leukemia transformation through serial trans-
plantation because of the rarity of this phenotype in the
Mll-AF4+VEC-Cre+ cohort (Figure 3A). Overall, these
results suggest that maternal immune activation
through a single dose of poly(I:C) is not sufficient to
trigger MLL-AF4-driven leukemogenesis.
Mll-AF4+VEC-Cre+ aging mice have a higher
proportion of CD3+ T-lymphoid cells in the spleen
Our previous studies have focused mainly on the
changes conferred by Mll-AF4 in embryos and younger
mice, but we never assessed the effect of Mll-AF4 on
the hematopoietic compartment in Mll-AF4+VEC-Cre+
aging mice. We monitored their blood composition
throughout adult life (6−10 and 18 months) and sacri-
ficed the Mll-AF4+VEC-Cre+ and control cohorts at
Figure 3. A poly(I:C)-induced maternal immune activation is not sufficient to drive Mll-AF4 leukemogenesis. (A) Survival curve of the progeny
of pregnant dams injected with poly(I:C) at E14−E15 of embryonic development. (B) Body, (C) spleen, and (D) liver weights of mice at the end
of study (18 months old). (E) Postmortem photos of sick mice 1463 and 1681 (564 and 516 days old) and control mouse 1684 (577 days old).
Proportion of CD11b+ myeloid, CD3+ T-lymphoid, and B220+ B-lymphoid cells in the (F) bone marrow, (G) spleen, and (H) peripheral blood
of sick mice 1463 and 1681. Peripheral blood counts of (I) white blood cells, (J) red blood cells, and (K) platelets of sick mice 1463 and 1681.
(L) Postmortem photo of sick mouse NB1 (10 day-old) and age-matched control BL6/N mice. CD11b+ myeloid cells, CD3+ T-lymphoid cells,
and B220+CD19+ and B220+CD19- B-lymphoid cells in the (M) bone marrow and (N) spleen of sick mouse NB1. (O) IgM expression on the
B220+CD19− fraction of sick mouse NB1. (P) Overview of the hematopoietic features of all the sick mice (1463, 1681, and NB1). Statistical
differences were assessed using a nonparametric Mann−Whitney U test with a bilateral p value or a Gehan−Breslow−Wilcoxon test (survival
curve only) (*p < 0.05, **p < 0.01, ***p < 0.001).
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CD11b+Gr1+ myeloid cells in the peripheral blood did
not change with age (Figure 4B). We noted an increase
in B220+CD19+IgM+ mature B-lymphoid cells in 6- to
10-month-old mice, which normalized upon aging
(Figure 4C). This B-lymphoid bias is in line with our
previous studies [4,7]. No significant difference was
observed for B220+CD19+IgM− immature B-lymphoid
cells in the peripheral blood, regardless of Mll-AF4expression (Figure 4D). There was, however, a small
decrease in CD3+ T-lymphoid cells in the 6- to 10-
month-old mice (Figure 4E). At 18 months, we also
analyzed the bone marrow and spleen. There was no signif-
icant difference in the proportion of myeloid cells and
B-lymphoid cells in the bone marrow and spleen of aging
Mll-AF4+VEC-Cre+ compared with control mice
(Figure 4F−H). Interestingly, aging Mll-AF4+VEC-Cre+
mice showed an increase in CD3+ T-lymphoid cells in the
Figure 4. Mll-AF4+VEC-Cre+ aging mice have a higher proportion of CD3+ T-lymphoid cells in the spleen. (A) Experimental layout. Proportions of (B)
CD11b+Gr1+, (C) B220+CD19+IgM+, (D) B220+CD19+IgM−, and (E) CD3+ cells in the peripheral blood of the control and Mll-AF4+VEC-Cre+ aged
cohort at two time points. Proportions of (F) CD11b+Gr1+, (G) B220+CD19+IgM+, (H) B220+CD19+IgM−, and (I) CD3+ in the bone marrow and
spleen of the control and Mll-AF4+VEC-Cre+ cohort at the end of study (18 months old). Peripheral blood counts of (J) white blood cells, (K) red blood
cells, and (L) platelets of the control and Mll-AF4+VEC-Cre+ cohort at the end of study (18 months). Statistical differences were assessed using a non-
parametric Mann−Whitney U test with a bilateral p value (*p < 0.05, **p < 0.01, ***p < 0.001).
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blood cell, red blood cell, and platelet) were similar
between 18-month-old control and Mll-AF4+VEC-Cre+
mice (Figure 4J−L). Overall, these results support the
increased B-lymphoid potential conferred by Mll-AF4 in
younger mice, which becomes undetectable in aging mice.
Instead, aging mice have a higher proportion of CD3+
T-lymphoid cells, which may contribute to a hematological
malignancy in a small subset [4].
Mll-AF4 maintains the progenitor B-cell compartment
in the spleen of aging mice and decreases the bone
marrow HSC-MPP pool
We also verified the B-cell progenitor and precursor popu-
lations in the bone marrow and spleen of aging mice: pre-
pro-B, pro-B, and pre-B (Figure 5A,B). The proportions of
pre-pro-B, pro-B, and pre-B lymphoid cells were similar in
the bone marrow of Mll-AF4+VEC-Cre+ and control aging
mice (Figure 5A). Interestingly, we did not detect many
pre-pro-B and pre-B lymphoid cells in the spleen, whereaspro-B lymphoid cells were maintained (Figure 5B). These
results suggest that Mll-AF4 favors the maintenance
of pro-B cells in the spleen compared with pre-pro-B and
pre-B cells, but this is not sufficient to drive a full-blown
leukemia. In the bone marrow hematopoietic stem and pro-
genitor cell compartment, mice that expressed Mll-AF4 had
a trend toward fewer long-term HSCs and short-term HSCs
and significantly fewer MPPs (Figure 5C). The proportions
of LMPPs and LK-CLPs were similar for Mll-AF4+VEC-
Cre+ and control aging mice (Figure 5C). These results
suggest that Mll-AF4 can maintain the more mature pro-
genitor populations with age, but has a potentially negative
effect on the maintenance of the more primitive HSC-MPP
compartment.
Discussion
There is now abundant epidemiological and functional
evidence suggesting that an overstimulation of the
immune system can accelerate leukemia development
in the pediatric population [9], which is being validated
Figure 5. Mll-AF4 maintains the progenitor B-cell compartment in the spleen of aging mice and decreases the bone marrow HSC-MPP pool.
Proportions of pre-pro-B cells (B220+CD19−ckit+ IL7R+CD43+CD24−IgM−); pro-B cells (B220+CD19+ckit+IL7R+CD43+CD24+IgM−); and
pre-B cells (B220+CD19+ckit+IL7R+CD43−CD24+IgM−) in the (A) bone marrow and (B) spleen of the control and Mll-AF4+VEC-Cre+
cohort at the end of study (18 months). (C) Proportions of LT-HSC (LSK CD34−FLT3−IL7R−CD48−CD150+); ST-HSCs (LSK CD34+FLT3
−IL7R−CD48−CD150+); MPPs (LSK CD34+FLT3−IL7R−CD48+), LMPPs (LSK FLT3+) and LK-CLPs (Lineage−ckit+/low Sca1−/low) in
the bone marrow of the control and Mll-AF4+VEC-Cre+ cohort at the end of study (18 months). Statistical differences were assessed using a
nonparametric Mann−Whitney U test with a bilateral p value (*p < 0.05, **p < 0.01, ***p < 0.001).
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kemia [10,11]. Given the early onset and high concor-
dance of infant t(4;11) MLL-AF4 acute leukemia in
monozygotic twin studies, it is expected that most of
the events leading to leukemogenesis will occur during
fetal life [1]. The aim of our study was therefore to
determine whether exposure of fetal cells to inflamma-
tory signals can also contribute to the development of
MLL-AF4-driven infant leukemia. We wanted to assess
first if the target cell compartment (FL Mll-AF4+ LSK
cells) can directly respond to a viral or bacterial mimic
and, second, if maternal immune activation can lead to
full-blown t(4;11) MLL-AF4 acute leukemia.
We exposed FL Mll-AF4+ LSK cells directly to two
different stimuli: the viral mimic poly(I:C) and the bacterial
mimic LPS. FL Mll-AF4+ LSK cells express both Tlr3 and
Tlr4, the receptors recognized by poly(I:C) and LPS,
respectively. An exposure to poly(I:C) and LPS mimics did
not affect the proliferation, apoptosis, or clonogenicity of
FL Mll-AF4+ LSK cells, nor did it induce a differentiation
bias; however, LPS increased the proliferation within colo-
nies derived from FL Mll-AF4+ LSK cells placed into
B-lymphoid conditions, whereas poly(I:C) increased prolif-
eration in both myeloid and B-lymphoid conditions. This
suggests that viral and bacterial mimics target proliferation
at the more mature end of the hematopoietic spectrum.Interestingly, LPS exposure upregulated the expression of
Tlr3 which is recognized by poly(I:C), and an exposure to
poly(I:C) increased the expression of Tlr9, Mda5, and
Rig1. These results indicate that FL Mll-AF4+ LSK cells
are able to activate the Toll-like receptor signaling pathway
upon stimulation with poly(I:C) or LPS.
T(4;11) MLL-AF4 acute leukemia has a very unique
gene expression signature, which includes important
players such as Cdk6, Bcl2, Hoxa9, and Meis1 [19,20].
We assessed the expression of 16 known candidate
genes in FL Mll-AF4+ LSK cells exposed to poly(I:C)
or LPS: Mll-AF4, Mll, Af4, Bcl2, Cdk6, E2a, Flt3,
Hmga2, Hoxa9, Ikaros, Il7r, Lmo2, Mcl1, Meis1, Pax5
and Twist1. FL Mll-AF4+ LSK cells exposed to poly(I:
C) upregulated Mll-AF4, Mll, Af4, Cdk6, Hmga2,
Hoxa9, Il7r, Lmo2, and Mcl1 and lost Flt3 expression.
LPS, on the other hand, had little effect, apart from a
slight downregulation of Bcl2 and Meis1. The lack of
effect of LPS on the MLL-AF4 gene expression signa-
ture could be due to the lower expression of its recep-
tor, Tlr4, compared with the poly(I:C) receptor Tlr3.
Importantly, the upregulation of the MLL-AF4 signa-
ture in response to poly(I:C) was dependent on Mll-
AF4 expression as control cells did not show this
effect. Our results suggest that FL Mll-AF4+ LSK cells
are potentially more sensitive to a viral mimic, and this
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signature genes.
Our results clearly illustrate the ability of HSPCs to
respond directly to poly(I:C) in vitro; however, it is
known that poly(I:C) can induce a more systemic inter-
feron response, the complexity of which cannot be
modeled in vitro. We therefore proceeded to stimulat-
ing the pregnant dam with poly(I:C) to mimic an in
vivo inflammatory response to a viral stimulus. It is
currently unknown if poly(I:C) can penetrate the pla-
cental barrier, suggesting that FL Mll-AF4+ LSK cells
are potentially protected from poly(I:C). However, a
maternal immune activation can compromise the pla-
cental barrier and allow passage of maternally derived
cytokines to the fetus, which can in turn activate its
immune response (reviewed in [21]). The plasma of
10-day-old mouse pups exposed to poly(I:C) during
gestation was shown to have increased levels of certain
cytokines (e.g., IL-2, IL-5, and IL-6), suggesting that
the inflammatory effect mediated by the exposure of
pregnant dams to poly(I:C) can persist after birth [22].
Cytokine expression in fetal tissue after a maternal
immune activation is also very dynamic: some changes
occur quickly (6 hours), whereas some changes become
noticeable after a longer period (24 hours) [23]. Given
the impact of a viral stimulation on brain development
[24], we injected pregnant dams with a single dose of
poly(I:C) to avoid complications in the offspring.
Maternal immune activation did not lead to the devel-
opment of a t(4;11) MLL-AF4 acute leukemia in the
offspring. Two Mll-AF4+VEC-Cre+ mice died at an
old age (564 and 516 days) and presented with a mye-
lodysplastic syndrome. One mouse was found dead
10 days after birth and presented with an expansion of
B220+CD19IgM cells. However, we could not
assess the leukemia transformation given the low
amount of material available, so we cannot conclude
that the cause of death is a hematological malignancy.
These results are in line with other studies indicating
that animal models that rely solely on Mll-AF4 and
mouse cells do not develop a full-blown leukemia
[2,4]. MLL-AF4-driven leukemogenesis in mice
appears to require additional factors to complete the
transformation process. These factors could be cell
intrinsic through the aberrant expression of a particular
gene such as the reciprocal fusion AF4-MLL, but could
also come from the microenvironment [25−27].
Given the negative results of the adult cohort, we
did not investigate the types of cytokines released upon
the maternal immune activation. Instead, we analyzed
the hematopoietic composition in aging mice to assess
hematopoietic differentiation and composition of the
progenitor and precursor B-lymphoid and hematopoi-
etic stem and progenitor pools. We found an increased
proportion of B220+CD19+IgM+ B-lymphoid cells anda decrease in CD3+ T-lymphoid cells in the peripheral
blood of younger Mll-AF4+VEC-Cre+ mice compared
with control mice. However, this normalized with age,
supporting the notion that there is a developmental
window of opportunity in which the disease can arise
[4]. Aging Mll-AF4+VEC-Cre+ mice displayed a
higher proportion of CD3+ T-lymphoid cells in their
spleen instead. The bone marrow progenitor and pre-
cursor B-lymphoid pools were similar in control and
Mll-AF4+VEC-Cre+ mice, but pro-B cells were prefer-
entially maintained in the spleen. This suggests that
Mll-AF4 confers an advantage in maintaining the pro-
B-lymphoid cell pool, which is similar to the leukemic
blasts observed in patients. However, there is a missing
component that could drive this to a full-blown leuke-
mia. The HSC-MPP frequency was reduced in Mll-AF4
+VEC-Cre+ aging mice compared with control mice,
whereas the LMPPs and LK-CLPs remained similar.
This suggests that Mll-AF4 can maintain the hemato-
poietic progenitor pool better than the stem cell pool
during aging. The cohort of aged mice had initially
received a single dose of poly(I:C) via the pregnant
dam; however, because of the mild effect of poly(I:C)
initially, it is unlikely that the aging symptoms are
influenced by poly(I:C), but instead are entirely due to
the influence of Mll-AF4.
Overall, this study shows that FL Mll-AF4+ LSK
cells are sensitive to viral and bacterial mimics, but the
MLL-AF4 gene expression signature only changes with
the viral mimic. The maternal immune activation with
a single exposure to poly(I:C) is not enough to trigger
MLL-AF4 leukemogenesis. Future studies will be nec-
essary to assess if a constant maternal immune activa-
tion of the pregnant dam and offspring can trigger
MLL-AF4-driven leukemogenesis and, if so, what
pathogens are involved.Acknowledgements
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